The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant
advancement in the treatment of chronic lymphocytic leukemia and related B-cell …

Objective: To review and summarize data on idelalisib, which was approved by the Food
and Drug Administration (FDA) in July 2014 for use in combination with rituximab for …

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-
like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase …

Protein tyrosine kinases are enzymes that catalyze the transfer of phosphate groups from
ATP to tyrosine residues on other proteins as substrate. Phosphorylation at tyrosine residues …

The Bruton's Tyrosine Kinase Inhibitor, ibrutinib, has been widely employed due to its
significant efficacy in B-cell lymphoma. However, the subsequent cardiac complications …

Functional ex vivo assays that predict a patient's clinical response to anticancer drugs for
guiding cancer treatment have long been a goal, but few have yet proved to be reliable. To …

Molecularly targeted anticancer therapy involves the use of drugs or other substances
affecting specific molecular targets that play a part in the development, progression and …

Bruton's tyrosine kinase (BTK) is expressed in B-cell malignancies, playing an important role
in B-cell receptor (BCR) signaling and offering a promising new strategy for the development …

The goal of the current study is to perform a pilot study of the cost of some oncohematology
diseases in Bulgaria. This is a pilot broader burden of disease research. The official report of …

Objective/background Membranoproliferative glomerulonephritis (MPGN) is a common
extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present …